top of page

Forum Posts

francoishofer
Nov 22, 2024
In Podcast discussions
In this episode Michael and Raju discuss the PReS endorsed points to consider for Treat to Target in childhood lupus. References : Smith EMD, Aggarwal A, Ainsworth J On behalf of the cSLE T2T International Task Force, et al Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force Annals of the Rheumatic Diseases 2023;82:788-798. Share your thoughts and experience and questions with us in the comments.
Episode 20 - Optimizing care in pediatric lupus using the new buzz word-treat to target content media
0
0
3
francoishofer
Nov 15, 2024
In Podcast discussions
Corticosteroids are widely used by several subspecialists -notably rheumatologists.Their use constitutes the commonest cause of osteoporosis in children. Michael And Raju discuss diagnosis and management strategies of this problem, where the treating physician is often between the devil and the deep sea. References to the article : Brunetto O, Cassinelli HR, Espada G, Viterbo GL, Meiorin SM, Ahumada MF, Brenzoni L, Maher MC, Chavero I, Ramírez Stieben LA, Brance ML. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics. Arch Argent Pediatr. 2024 Apr 1;122(2):e202202948. English, Spanish. doi: 10.5546/aap.2022-02948.eng. Epub 2023 Jul 6. PMID: 37382585. Sakka SD, Cheung MS. Management of primary and secondary osteoporosis in children. Ther Adv Musculoskelet Dis. 2020 Nov 2;12:1759720X20969262. doi: 10.1177/1759720X20969262. PMID: 33224280; PMCID: PMC7649886. Share your thoughts and experience and questions with us in the comments.
Episode 19 - Corticosteroids and Osteoporosis in children content media
0
0
4
francoishofer
Oct 25, 2024
In Podcast discussions
References to the article : Hernandez, A., Zapata Leiva, L., Mutka, M. et al. Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review. Pediatr Rheumatol 22, 77 (2024). Share your thoughts and experience and questions with us in the comments.
Episode 18 - Easy to see, but difficult to measure: How to evaluate the outcome of local scleroderma? content media
0
0
4
francoishofer
Oct 04, 2024
In Podcast discussions
References to the article : Sestan M, Jelusic M. Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives. Pediatric Health Med Ther. 2023 Mar 7;14:89-98. doi: 10.2147/PHMT.S379862. PMID: 36915829; PMCID: PMC10008002. Parums DV. A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future. Med Sci Monit. 2024 Jan 28;30:e943912. doi: 10.12659/MSM.943912. PMID: 38281080; PMCID: PMC10832303. Share your thoughts, experiences, and questions with us.
Episode 17 - IgA Vasculitis Nephritis Tips on Diagnosis and Management for the Practitioner content media
0
0
10
francoishofer
Sep 30, 2024
In Podcast discussions
References to the article : Balevic SJ, Gonzalez D, and al-., with the CARRA Registry investigators. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. Lupus Sci Med. 2022 Nov;9 Haładyj E, Olesińska M, and al.- Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia. 2018 Garg S, Chewning B, Bartels CM, and al. Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares. Arthritis Care Res (Hoboken). 2024 Feb Share your thoughts, experiences, and questions with us.
Episode 16 - Monitoring blood levels of  HCQ  to  prevent Lupus flare  content media
0
0
4
francoishofer
Sep 20, 2024
In Podcast discussions
References to the article : Francesco Baldo, Francesca Minoia, and al - Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project, Rheumatology, 2024;, keae391. Share your thoughts, experiences, and questions with us.
Episode 15 - How does the world treat MAS in 2024? content media
0
0
9
francoishofer
Sep 13, 2024
In Podcast discussions
References to the article discussed in the podcast : Burns JC, Jain S and al. - Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - Lancet Child Adolesc Health. 2021 Dec Share your thoughts, experiences, and questions with us.
Episode 14 - When the  first dose of IVIG fails in Kawasaki disease content media
0
0
5
francoishofer
Sep 06, 2024
In Podcast discussions
References to the article discussed in the podcast : Foddai SG, Sciascia S., and all - New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing. Int J Environ Res Public Health. 2023 May 10 Share your thoughts, experiences, and questions with us.
Episode 13 - Autoantibodies in saliva -the next frontier  content media
0
0
5
francoishofer
Aug 30, 2024
In Podcast discussions
References to the article discussed in the podcast : Delestre F, Terrier B and al. - Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2024 Jan 11;83(2):233-241. doi: 10.1136/ard-2023-224623. PMID: 37918894. Samman KN, Ross C, Pagnoux C, Makhzoum JP. Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives. Int J Rheumatol. 2021 Apr 8;2021:5534851. doi: 10.1155/2021/5534851. PMID: 33927768; PMCID: PMC8049818. Kimberly A.  David A. Cabral and al. - Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody–Associated Vasculitis - American College of Rheumatology, March 2021 Share your thoughts, experiences, and questions with us in the comments.
Episode 12 - ANCA vasculitis induction and maintenance. extrapolating from adults and when goalposts change ?  content media
0
0
7
francoishofer
Aug 23, 2024
In Podcast discussions
References to the article discussed in the podcast : Claudia Iannone, Roberto Caporali, Elisabetta Miserocchi and al., Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review, Children 2023 Share your thoughts, experiences, and questions with us in the comments.
Episode 11 - Tocilizumab and JIA associated uveitis content media
0
0
5
francoishofer
Jul 26, 2024
In Podcast discussions
References to the article discussed in the podcast : Lisa K Stamp, Carl Horsley, Leanne Te Karu, Nicola Dalbeth, Murray Barclay, Colchicine: the good, the bad, the ugly and how to minimize the risks, Rheumatology, Volume 63, Issue 4, April 2024, Pages 936–944 Share your thoughts, experiences, and questions with us in the comments.
Episode 10 - Colchicine - a simple drug for complex problems content media
0
0
5
francoishofer
Jul 26, 2024
In Podcast discussions
References to the article discussed in the podcast : Del Giudice E, Marcellino A, Hoxha S, Martucci V, Sanseviero M, Bloise S, De Maria SG, Leone MR, Ventriglia F, Lubrano R. Proteinuria and hematuria as early signs of renal involvement in juvenile idiopathic arthritis. Front Pediatr. 2024 Jun 4;12:1395961. doi: 10.3389/fped.2024.1395961. PMID: 38895193; PMCID: PMC11184124. Bohr AH, Fuhlbrigge RC, Pedersen FK, de Ferranti SD, Müller K. Premature subclinical atherosclerosis in children and young adults with juvenile idiopathic arthritis. A review considering preventive measures. Pediatr Rheumatol Online J. 2016 Jan 6;14(1):3. doi: 10.1186/s12969-015-0061-5. PMID: 26738563; PMCID: PMC4704268. Share your thoughts, experiences, and questions with us in the comments.
Episode 09 - Should we be monitoring the kidney in JIA? content media
0
0
13
francoishofer
Jul 26, 2024
In Podcast discussions
References to the article discussed in the podcast : Huang, Y., Deng, J., Liu, J. et al. Autoimmune congenital heart block: a case report and review of the literature related to pathogenesis and pregnancy management. Arthritis Res Ther 26, 8 (2024). https://doi.org/10.1186/s13075-023-03246-w Share your thoughts, experiences, and questions with us in the comments.
Episode 08 - Fetal bradycardia and the pediatric rheumatologist. content media
0
0
3
francoishofer
Jul 19, 2024
In Podcast discussions
References to the article discussed in the podcast : Reiser. C., Klotsche. J., Hospach. T. and al. Long-term follow-up of children with chronic non-bacterial osteomyelitis—assessment of disease activity, risk factors, and outcome. Arthritis Share your thoughts, experiences, and questions with us in the comments.
Episode 07- Counselling the family of a child with Chronic Non bacterial Osteitis  content media
0
0
5
francoishofer
Jul 12, 2024
In Podcast discussions
References to the article discussed in the podcast : Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents - Sener Sener, Seza Ozen and al. - Rheumatology (Oxford). 2022 Nov Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Nakaoka Y, Nishimoto N. and al. - Rheumatology (Oxford). 2020 Sep Share your thoughts, experiences, and questions with us here.
Episode 06 - Tocilizumab - expanding uses !? content media
0
0
5
francoishofer
Jul 05, 2024
In Podcast discussions
References to the article discussed in the podcast : PFAPA syndrome: A review on treatment and outcome - Federica Vanoni, Katerina Theodoropoulou, Michael Hofer. The use of ketotifen as long-term anti-inflammatory prophylaxis in children with PFAPA syndrome - Lenka Kapustova, Milos Jesenak and al. Share your thoughts, experiences, and questions with us here.
Episode 05 - New treatments for PFAPA syndrome content media
2
0
8
francoishofer
Jun 28, 2024
In Podcast discussions
References to the article discussed in the podcast : Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, Smolen JS, Aletaha D, O'Shea J, Laurence A. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024 Jan 11;83(2):139-160. doi: 10.1136/ard-2023-223850. PMID: 37923366; PMCID: PMC10850682. Welzel, T., Winskill, C., Zhang, N. et al. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol 19, 46 (2021). https://doi.org/10.1186/s12969-021-00514-4 JAKi posology : Recently FDA Approved for Poly JIA - 2 yrs and older (10-19 kg) 3.2 mg bd  20-39 kg 4mg bd . > 40 kg 5mg bd Additional resource on the same topic published after the recording : https://www.researchgate.net/publication/381276770_Safety_and_efficacy_of_tofacitinib_for_the_treatment_of_patients_with_juvenile_idiopathic_arthritis_preliminary_results_of_an_open-label_long-term_extension_study Share your thoughts, experiences, and questions with us !
Episode 04 - What we know about JAKi in pediatric rheumatology content media
0
0
11
francoishofer
Jun 21, 2024
In Podcast discussions
References to the article discussed in the podcast : Incidence of Orofacial Manifestations of Juvenile Idiopathic Arthritis From Diagnosis to Adult Care Transition: A Population‐Based Cohort Study - Glerup - 2023 - Arthritis & Rheumatology - Wiley Online Library Stoustrup P, Herlin T, Spiegel L, Rahimi H, Koos B, Pedersen TK, Twilt M; Temporomandibular Joint Juvenile Arthritis Working Group. Standardizing the Clinical Orofacial Examination in Juvenile Idiopathic Arthritis: An Interdisciplinary, Consensus-based, Short Screening Protocol. J Rheumatol. 2020 Sep 1;47(9):1397-1404. doi: 10.3899/jrheum.190661. Epub 2019 Dec 1. PMID: 31787607. Share your thoughts, experiences, and questions with us !
Episode 03 -The many "faces" of JIA - TMJ involvement. content media
1
0
10
francoishofer
Jun 14, 2024
In Podcast discussions
References to the article discussed in the podcast : MTX intolerance in children and adolescents with juvenile idiopathic arthritis Focus on Tables 1 and 2 Share your thoughts, experiences, and questions with us: • From anti-emetics to hypnosis the choice is wide. What techniques do you use?
Episode 02 - Methotrexate and vomiting content media
1
0
11
francoishofer
May 21, 2024
In Podcast discussions
References to the article discussed in the podcast : Zajc Avramovič, M., Toplak, N., Markelj, G. et al. Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection. Arthritis Res Ther 26, 69 (2024). Share your thoughts, experiences, and questions with us: 1. Have you dealt with joint injections for oligoarthritis? 2. Do you have a personal story or experience related to managing oligoarthritis? 3. Is triamcinolone hexacetonide available in your center? 4. How do you inform the patient/parents about the risk of arthritis recurrence?
Episode 01 - "Will my child need yet another joint injection?" content media
2
0
49

francoishofer

Admin
More actions
bottom of page